Facebook Pixel SOARING SOUTH KOREAN MEDICAL DEVICES MARKET | BioSpectrum Asia - Business - Lees dit verhaal op Magzter.com

Poging GOUD - Vrij

SOARING SOUTH KOREAN MEDICAL DEVICES MARKET

BioSpectrum Asia

|

BioSpectrum Asia Sep 2021

The pandemic induced rise in healthcare expenditure has catalysed the growth of the medical devices market. Growing healthcare needs are significantly influencing the development of novel diagnostic and surgical tools. To meet the regional and international demand for medical devices, South Korea is taking all the necessary steps to support the country’s major market players. We shall take a closer look at the big movers and shakers of the industry.

- Hithaishi C. Bhaskar

SOARING SOUTH KOREAN MEDICAL DEVICES MARKET

In May 2021, Ministry of Food and Drug Safety (MFDS), government of South Korea reported that for the first time ever, the number of medical devices produced by local companies has surpassed those imported from other countries since 2011. The number of local companies’ medical devices reported to the government in 2020 reached 4,222, accounting for 51.6 per cent in the market. The total number of reported medical devices, including imports, reached 8,183, slightly down from 8,269 in 2019. The COVID-19 pandemic was a major factor contributing to the increase in locally produced devices.

In 2020, around 249 COVID-19 test kits received production and export approvals, accounting for 22 per cent of all medical devices with manufacturing approvals.

A sudden surge in Artificial Intelligence (AI)- powered medical devices was witnessed in 2020 with around 50 devices being approved compared to only 10 devices in 2019. Out of which, 45 were developed by local companies, and five were imported, mostly under the category of AI-based telemedicine software.

Trends and drivers

Post pandemic, the South Korean government is sensing a strong business opportunity to boost the economy which suffered during the pandemic. With an increase in overseas demand for Korean-made medical devices, domestic manufacturers are targeting the international market with competitive prices and services. After successfully containing COVID-19 with mostly domestically produced aids, the country is keen on boosting the competitiveness of the regional medtech sector by emphasis on manufacture of futuristic medical tools.

According to the Ministry of Economy and Finance, the country’s biohealth exports have shown a high annual growth of about 40 to 50 per cent since the pandemic. The number of pharmaceutical and biotech companies with sales exceeding 1 trillion won ($868 million) also doubled from six in 2018 to 12 in 2020.

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Alphamab Oncology appoints Fei Wang as Chief Financial Officer

Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market

DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

PHCbi introduces LiCellGrow Cell Expansion System

PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences

CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala

Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation

Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Argo Biopharma ropes in Dr Gena Wang as CFO and CSO

China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust

The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Korea designs model for accurate and scalable drug-drug interaction prediction

A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.

time to read

1 min

BioSpectrum Asia April 2027

Translate

Share

-
+

Change font size